\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\,\\ including\\ cn\\ i\\-xii\\,\\ within\\ normal\\ limits\\.\\ csf\\ positive\\ for\\ two\\ oligoclonal\\ bands\\.\ \(0\)\
\-\ patient\\ admitted\\ and\\ recieved\\ solumedrol\\ x\\ 5\\ days\\.\\ \\ then\\ discharged\\ to\\ home\\ with\\ followup\\ in\\ three\\ months\\ after\\ repeat\\ mri\\ brain\\ and\\ c\\-spine\\.\\ \\ in\\ the\\ event\\ of\\ an\\ another\\ episode\\,\\ immunomodulating\\ therapy\\ to\\ be\\ initiated\\.\ \(0\)\
\-\ the\\ cervical\\ spine\\ demonstrates\\ t2\\ hyperintensity\\ within\\ the\\ cord\\ at\\ c3\\ and\\ c4\\ with\\ mild\\ expansion\\ of\\ the\\ cord\\.\\ \ \(0\)\
\-\ enhancement\\ in\\ the\\ right\\ side\\ of\\ the\\ brain\\ and\\ enhancement\\ adjacent\\ to\\ the\\ posterior\\ horn\\ of\\ the\\ left\\ lateral\\ ventricle\\ are\\ well\\ visualized\\ on\\ axial\\ t1\\ post\\ gadolinium\\ mri\\.\ \(0\)\
\-\ these\\ high\\ signal\\ lesions\\ are\\ consistent\\ with\\ demylination\\.\ \(0\)\
\-\ multiple\\ sclerosis\ \(41\)\
\-\ \\â\\€\\¢\\ cns\\ infection\\ \\(lyme\\ disease\\,\\ syphilis\\,\\ hiv\\ infection\\,\\ human\\ t\\-lymphotrophic\\ virus\\ type\\ i\\)\ \(0\)\
\-\ \\â\\€\\¢\\ cns\\ inflammatory\\ condition\\ \\(sarcoidosis\\,\\ sle\\,\\ sj\\?gren\\'s\\ syndrome\\)\ \(0\)\
\-\ \\â\\€\\¢\\ cns\\ microvascular\\ disease\\ \\(htn\\,\\ dm\\,\\ vasculitis\\)\ \(0\)\
\-\ \\â\\€\\¢\\ genetic\\ disorder\\ \\(leukodystrophy\\,\\ hereditary\\ myelopathy\\,\\ mitochondrial\\ disease\\)\ \(0\)\
\-\ \\â\\€\\¢\\ structural\\ or\\ compressive\\ condition\\ of\\ the\\ brain\\ and\\ spinal\\ cord\ \(0\)\
\-\ \\â\\€\\¢\\ vitamin\\ b12\\ deficiency\ \(0\)\
\-\ \\â\\€\\¢\\ multiple\\ sclerosis\ \(0\)\
\-\ 21\\ y\\.o\\.\\ woman\\ with\\ 5\\-7d\\ h\\/o\\ cervical\\ neck\\ pain\\ associated\\ intermittent\\ shooting\\ and\\ tingling\\ pains\\ in\\ both\\ arms\\ \\(l\\>r\\)\\.\\ \\ \ \(0\)\
\-\ negative\\ medical\\ history\\,\\ family\\ history\\,\\ or\\ social\\ history\\.\\ \\ no\\ medications\\.\ \(0\)\
\-\ physical\\ symptoms\\,\\ mri\\ findings\\,\\ and\\ positive\\ csf\\ oligoclonal\\ bands\\ are\\ strongly\\ indicative\\ multiple\\ sclerosis\\.\\ \\ the\\ presence\\ of\\ cns\\ lesions\\ that\\ are\\ disseminated\\ in\\ time\\ and\\ space\\ with\\ no\\ better\\ explanation\\ for\\ the\\ disease\\ process\\ will\\ confirm\\ the\\ diagnosis\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ cns\\:\\ 0\\.06407131380917483\ \(0\)\
\-\ oligoclonal\\:\\ 0\\.047713797296501485\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.040179855169125325\ \(0\)\
\-\ bands\\:\\ 0\\.0373768963901992\ \(0\)\
\-\ cord\\:\\ 0\\.03568322989236705\ \(0\)\
\-\ sclerosis\\:\\ 0\\.03372873882886094\ \(0\)\
\-\ t\\-lymphotrophic\\:\\ 0\\.032291276278265564\ \(0\)\
\-\ 5\\-7d\\:\\ 0\\.032291276278265564\ \(0\)\
\-\ i\\-xii\\:\\ 0\\.02975227561687382\ \(0\)\
\-\ immunomodulating\\:\\ 0\\.02975227561687382\ \(0\)\
\-\ demylination\\:\\ 0\\.02975227561687382\ \(0\)\
\-\ gren\\:\\ 0\\.02975227561687382\ \(0\)\
\-\ solumedrol\\:\\ 0\\.028267055440653437\ \(0\)\
\-\ brain\\:\\ 0\\.028256610146184198\ \(0\)\
\-\ recieved\\:\\ 0\\.026395899309642482\ \(0\)\
\-\ condition\\:\\ 0\\.02618147552312715\ \(0\)\
\-\ csf\\:\\ 0\\.02614281576414661\ \(0\)\
\-\ leukodystrophy\\:\\ 0\\.025728054779261697\ \(0\)\
\-\ mitochondrial\\:\\ 0\\.025163400274399946\ \(0\)\
\-\ shooting\\:\\ 0\\.025163400274399946\ \(0\)\
\-\ sj\\:\\ 0\\.02467427429409034\ \(0\)\
\-\ b12\\:\\ 0\\.02467427429409034\ \(0\)\
\-\ microvascular\\:\\ 0\\.024242834603041313\ \(0\)\
\-\ pains\\:\\ 0\\.023856898648250743\ \(0\)\
\-\ explanation\\:\\ 0\\.023189054117869954\ \(0\)\
\-\ cervical\\:\\ 0\\.022747922392612665\ \(0\)\
\-\ human\\:\\ 0\\.022624399613008203\ \(0\)\
\-\ myelopathy\\:\\ 0\\.022371678472030358\ \(0\)\
\-\ mri\\:\\ 0\\.021574459944116702\ \(0\)\
\-\ syphilis\\:\\ 0\\.02096877644911422\ \(0\)\
\-\ virus\\:\\ 0\\.020500522341019404\ \(0\)\
\-\ disease\\:\\ 0\\.020465018918911417\ \(0\)\
\-\ positive\\:\\ 0\\.020314180148601587\ \(0\)\
\-\ c4\\:\\ 0\\.020218613765429192\ \(0\)\
\-\ structural\\:\\ 0\\.019956859318608147\ \(0\)\
\-\ c3\\:\\ 0\\.019832677810638615\ \(0\)\
\-\ dm\\:\\ 0\\.019832677810638615\ \(0\)\
\-\ multiple\\:\\ 0\\.019778087950321637\ \(0\)\
\-\ lyme\\:\\ 0\\.019374204759525043\ \(0\)\
\-\ compressive\\:\\ 0\\.019374204759525043\ \(0\)\
\-\ initiated\\:\\ 0\\.019268023305776864\ \(0\)\
\-\ c\\-spine\\:\\ 0\\.019164833280257833\ \(0\)\
\-\ disseminated\\:\\ 0\\.019064470737444224\ \(0\)\
\-\ tingling\\:\\ 0\\.01877889732546726\ \(0\)\
\-\ sle\\:\\ 0\\.0186884481950996\ \(0\)\
\-\ vitamin\\:\\ 0\\.01842977578772248\ \(0\)\
\-\ social\\:\\ 0\\.018266948818598548\ \(0\)\
\-\ infection\\:\\ 0\\.018197923619581006\ \(0\)\
\-\ hereditary\\:\\ 0\\.017961521679627664\ \(0\)\
\-\ indicative\\:\\ 0\\.017888984583304658\ \(0\)\
\-\ arms\\:\\ 0\\.017481564674476\ \(0\)\
\-\ strongly\\:\\ 0\\.017417858657216408\ \(0\)\
\-\ hiv\\:\\ 0\\.017355241685204317\ \(0\)\
\-\ event\\:\\ 0\\.01729367714924688\ \(0\)\
\-\ hyperintensity\\:\\ 0\\.0172331302556527\ \(0\)\
\-\ htn\\:\\ 0\\.0172331302556527\ \(0\)\
\-\ genetic\\:\\ 0\\.017114958599175698\ \(0\)\
\-\ are\\:\\ 0\\.017067749048052774\ \(0\)\
\-\ horn\\:\\ 0\\.01700048041784198\ \(0\)\
\-\ deficiency\\:\\ 0\\.016889471811631987\ \(0\)\
\-\ cn\\:\\ 0\\.016835204098133303\ \(0\)\
\-\ enhancement\\:\\ 0\\.016780137480754843\ \(0\)\
\-\ lesions\\:\\ 0\\.01675868502816079\ \(0\)\
\-\ h\\/o\\:\\ 0\\.016332635887461196\ \(0\)\
\-\ better\\:\\ 0\\.016149447533707856\ \(0\)\
\-\ vasculitis\\:\\ 0\\.016017828452293707\ \(0\)\
\-\ confirm\\:\\ 0\\.015932638480996023\ \(0\)\
\-\ \\,\\:\\ 0\\.015865791385628564\ \(0\)\
\-\ episode\\:\\ 0\\.015496523609142587\ \(0\)\
\-\ expansion\\:\\ 0\\.015422521018235921\ \(0\)\
\-\ physical\\:\\ 0\\.015359012963965116\ \(0\)\
\-\ followup\\:\\ 0\\.01494256401308426\ \(0\)\
\-\ home\\:\\ 0\\.014878857995824666\ \(0\)\
\-\ gadolinium\\:\\ 0\\.014847415711240814\ \(0\)\
\-\ repeat\\:\\ 0\\.014724277942746363\ \(0\)\
\-\ discharged\\:\\ 0\\.014350471150240244\ \(0\)\
\-\ l\\:\\ 0\\.014269368125048986\ \(0\)\
\-\ r\\:\\ 0\\.014216280186211745\ \(0\)\
\-\ 21\\:\\ 0\\.014163950672484726\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.014138063613059478\ \(0\)\
\-\ disorder\\:\\ 0\\.014061482349985069\ \(0\)\
\-\ medications\\:\\ 0\\.013961802630113696\ \(0\)\
\-\ admitted\\:\\ 0\\.013522177452612598\ \(0\)\
\-\ another\\:\\ 0\\.013457343836863875\ \(0\)\
\-\ intermittent\\:\\ 0\\.01343598515440676\ \(0\)\
\-\ \\(\\:\\ 0\\.013230068246224552\ \(0\)\
\-\ \\)\\:\\ 0\\.013068455899511083\ \(0\)\
\-\ history\\:\\ 0\\.012969390524253666\ \(0\)\
\-\ i\\:\\ 0\\.0129388816675037\ \(0\)\
\-\ limits\\:\\ 0\\.012901881315904784\ \(0\)\
\-\ family\\:\\ 0\\.01282898331474253\ \(0\)\
\-\ visualized\\:\\ 0\\.012670081132946834\ \(0\)\
\-\ \\?\\:\\ 0\\.012215675826463395\ \(0\)\
\-\ process\\:\\ 0\\.012051521922471482\ \(0\)\
\-\ within\\:\\ 0\\.011942354640191074\ \(0\)\
\-\ ventricle\\:\\ 0\\.011730367463657245\ \(0\)\
\-\ presence\\:\\ 0\\.011361852082260546\ \(0\)\
\-\ including\\:\\ 0\\.011301899783856864\ \(0\)\
\-\ spinal\\:\\ 0\\.01120797146659189\ \(0\)\
\-\ then\\:\\ 0\\.01113907281473293\ \(0\)\
\-\ inflammatory\\:\\ 0\\.01085463715821254\ \(0\)\
\-\ side\\:\\ 0\\.010844126380088172\ \(0\)\
\-\ three\\:\\ 0\\.010551737100171833\ \(0\)\
\-\ type\\:\\ 0\\.010551737100171833\ \(0\)\
\-\ \\>\\:\\ 0\\.010399881006111958\ \(0\)\
\-\ space\\:\\ 0\\.010353688670610383\ \(0\)\
\-\ x\\:\\ 0\\.010326250312628122\ \(0\)\
\-\ spine\\:\\ 0\\.010308071597089186\ \(0\)\
\-\ t1\\:\\ 0\\.009921229070418475\ \(0\)\
\-\ adjacent\\:\\ 0\\.00989683605909988\ \(0\)\
\-\ post\\:\\ 0\\.009856538582682395\ \(0\)\
\-\ will\\:\\ 0\\.00979297076329356\ \(0\)\
\-\ medical\\:\\ 0\\.009631171428813203\ \(0\)\
\-\ days\\:\\ 0\\.009593678740556694\ \(0\)\
\-\ negative\\:\\ 0\\.009348425499541664\ \(0\)\
\-\ neck\\:\\ 0\\.009191366802265503\ \(0\)\
\-\ 5\\:\\ 0\\.009158096785509755\ \(0\)\
\-\ y\\.o\\:\\ 0\\.00903435689592198\ \(0\)\
\-\ two\\:\\ 0\\.008964583287970717\ \(0\)\
\-\ syndrome\\:\\ 0\\.008952038742617734\ \(0\)\
\-\ axial\\:\\ 0\\.008933302110138723\ \(0\)\
\-\ t2\\:\\ 0\\.00885929951923206\ \(0\)\
\-\ time\\:\\ 0\\.008841030136407739\ \(0\)\
\-\ high\\:\\ 0\\.008566102787827164\ \(0\)\
\-\ months\\:\\ 0\\.008549235511685228\ \(0\)\
\-\ therapy\\:\\ 0\\.00836864760527697\ \(0\)\
\-\ signal\\:\\ 0\\.008253019524808712\ \(0\)\
\-\ mild\\:\\ 0\\.0082426866444364\ \(0\)\
\-\ these\\:\\ 0\\.00814595125259282\ \(0\)\
\-\ both\\:\\ 0\\.007993406559289823\ \(0\)\
\-\ symptoms\\:\\ 0\\.007800943138821023\ \(0\)\
\-\ in\\:\\ 0\\.0077178979879167576\ \(0\)\
\-\ consistent\\:\\ 0\\.007675085233813931\ \(0\)\
\-\ associated\\:\\ 0\\.007386309750577662\ \(0\)\
\-\ or\\:\\ 0\\.0073371629960711175\ \(0\)\
\-\ woman\\:\\ 0\\.007230413727065591\ \(0\)\
\-\ posterior\\:\\ 0\\.007214793218690288\ \(0\)\
\-\ diagnosis\\:\\ 0\\.007187616596265274\ \(0\)\
\-\ well\\:\\ 0\\.00708088261160678\ \(0\)\
\-\ \\'s\\:\\ 0\\.00690126966434815\ \(0\)\
\-\ exam\\:\\ 0\\.006876314798349956\ \(0\)\
\-\ demonstrates\\:\\ 0\\.006837440299095919\ \(0\)\
\-\ lateral\\:\\ 0\\.006764351815474543\ \(0\)\
\-\ findings\\:\\ 0\\.0066624063582049805\ \(0\)\
\-\ after\\:\\ 0\\.00647619488135239\ \(0\)\
\-\ no\\:\\ 0\\.006303620151676205\ \(0\)\
\-\ the\\:\\ 0\\.006076891635324212\ \(0\)\
\-\ that\\:\\ 0\\.005406522815233785\ \(0\)\
\-\ for\\:\\ 0\\.00534145163840817\ \(0\)\
\-\ and\\:\\ 0\\.005274989178966108\ \(0\)\
\-\ normal\\:\\ 0\\.004907005328201835\ \(0\)\
\-\ be\\:\\ 0\\.004826947704556517\ \(0\)\
\-\ to\\:\\ 0\\.004693056136736113\ \(0\)\
\-\ an\\:\\ 0\\.004328442726317692\ \(0\)\
\-\ at\\:\\ 0\\.004240890669712941\ \(0\)\
\-\ pain\\:\\ 0\\.0038227405404056215\ \(0\)\
\-\ left\\:\\ 0\\.00350221710356379\ \(0\)\
\-\ right\\:\\ 0\\.0033026802531517093\ \(0\)\
\-\ patient\\:\\ 0\\.0031376993806461096\ \(0\)\
\-\ on\\:\\ 0\\.002651615429909993\ \(0\)\
\-\ of\\:\\ 0\\.002560523094461284\ \(0\)\
\-\ with\\:\\ 0\\.0021429336280199586\ \(0\)\
\-\ \\.\\:\\ 0\\.0018204890306331423\ \(0\)\
